Novel detection and tracking method on the epidermal growth factor receptor using fluorescent nanodiamonds

• Main Authors: Su, Hung-Cheng, 蘇泓政
• Other Authors: Chao, Jui-I
• Format: Others
• Language: en_US
• Published: 2014
• Online Access: http://ndltd.ncl.edu.tw/handle/7j9q72

碩士 === 國立交通大學 === 分子醫學與生物工程研究所 === 102 === Fluorescent nanodiamond (FND) is a promising biocompatible nanomaterial that is developed for bio-imaging and -detection. Here we show cetuximab, a specific epidermal growth factor receptor (EGFR) monoclonal antibody, which can be conjugated on the surface of FNDs for tracking the EGFR of human lung cancer cells in vitro and in vivo. The FND’s surface was modified with carboxylation, which contained negative charge. The optimal binding ratio of FND: cetuximab was approximate 1:0.25. The average size of FND was 113.9 ± 4.9 nm. The average size of FND-cetuximab complexes was around 192.0 ± 8.1 nm. FND-cetuximab can specifically bind on the EGFR proteins of human lung cancer cells using immunoprecipitation method and confocal microscopy. The binding image of single FND-cetuximab and EGFR on a protein G bead can be directly observed under confocal microscope after immunoprecipitation. Moreover, FND-cetuximab can recognize the EGFR to increase the uptake ability of lung cancer cells. FND-cetuximab-EGFR complexes were transported to lysosomes for EGFR degradation. Taken together, these findings demonstrate the FND-cetuximab complex that can be used for the novel targeting detection and tracking method on the EGFR in the human lung cancer cells.